Esnotin Tablet contains Betahistine 16 mg, a histamine analog used primarily in the management of Ménière’s disease and other vestibular disorders characterized by vertigo, tinnitus, and hearing loss. Betahistine acts as a partial agonist at histamine H1 receptors and an antagonist at H3 receptors, resulting in improved microcirculation in the inner ear and reduction of endolymphatic pressure. This pharmacological action helps alleviate symptoms associated with vestibular dysfunction by enhancing blood flow and reducing abnormal sensory signals. Esnotin is indicated for the treatment of vertigo of peripheral origin, including Ménière’s disease, vestibular neuronitis, and labyrinthitis. The recommended dosage is typically 16 mg taken two to three times daily, adjusted according to clinical response and tolerability. Esnotin is generally well tolerated; however, mild adverse effects such as headache, gastrointestinal discomfort, and allergic reactions may occur. It should be used cautiously in patients with peptic ulcer disease or asthma due to potential histamine-related effects. Esnotin Tablet is contraindicated in patients with hypersensitivity to Betahistine or any excipients. Clinical monitoring is advised to assess therapeutic efficacy and detect any adverse reactions. As with all medications, Esnotin should be used under medical supervision to ensure optimal outcomes in vestibular disorder management.